How ASX shares vs. property performed in May

We reveal the property price growth for each city and regional market and the top 5 risers of the ASX 200.

Real estate agent and client exploring property.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big news in shares vs. property is Brisbane overtaking Canberra as Australia's second-most expensive city, with the median home value in the Sunshine State's capital rising 1.4% last month.

The last time Brisbane was the second highest-value capital city in Australia was 27 years ago, in 1997.

The national median home value, which reflects all types of property in a single data point, rose for a 16th month, up 0.8%, according to CoreLogic data. The median house and apartment prices lifted 0.8% as well.

Meantime, the S&P/ASX 200 Index (ASX: XJO) rose 0.49%, thus recovering only a sliver of its 3% loss in April. But as usual, some stocks shot the lights out, including an ASX biotech that screamed 20.6% higher.

CoreLogic research director Tim Lawless said the May increase in the median home value was the strongest monthly gain since October 2023.

A lack of stock for sale in the strongest markets, which continue to be the mid-sized capital cities, once again powered the national benchmark increase.

Lawless commented:

The number of properties available for sale in Perth and Adelaide remain more than -40% below the five-year average for this time of the year while Brisbane listings are -34% below average.

Inventory levels in these markets remain well below average despite vendor activity lifting relative to this time last year.

Fresh listings are being absorbed rapidly by market demand, keeping stock levels low and upwards pressure on prices.

Perth, Adelaide and Brisbane recorded the highest home value growth in May at 2%, 1.8%, and 1.4%, respectively.

Among the regional markets, regional Western Australia dominated with 1.8% growth, followed by regional South Australia with 1.4%, and regional Queensland with 1.1%.

Shares vs. property price growth in May

Here's how shares vs. property performed in terms of house price growth and share price growth in May.

Property marketMedian house pricePrice growth in May12-month price growth
Hobart $697,770(0.5%)(0.1%)
Darwin $584,5380.7%3.8%
Regional New South Wales$762,5060.4%4.2%
Regional Victoria$603,432(0.3%)(0.6%)
Regional Queensland$634,9881%11.7%
Regional South Australia$430,3891.5%10.7%
Regional Western Australia$519,3111.8%15.2%
Regional Tasmania$534,8010.1%0.1%
Regional Northern Territory$450,4310%(6.1%)
Source: CoreLogic

Top 5 risers of the ASX 200 in May

The S&P/ASX 200 Index (ASX: XJO) lifted 0.49% in May.

According to CommSec data, these 5 ASX 200 shares were the outperformers.

ASX 200 shareShare price growth in May
Telix Pharmaceuticals Ltd (ASX: TLX)20.6%
PEXA Group Ltd (ASX: PXA)19.3%
Alumina Ltd (ASX: AWC)16.6%
Pinnacle Investment Management Group Ltd (ASX: PNI)16.3%
A2 Milk Company Ltd (ASX: A2M) 16.1%
Source: CommSec

What drove the Telix Pharmaceuticals share price higher?

News released by Telix Pharmaceuticals on the final day of the month pushed the biotech share to the top of the ASX 200 group. The Telix Pharmaceuticals share price soared 15.31% on 31 May alone.

Telix is a commercial-stage biopharmaceutical company. It develops diagnostic and therapeutic products to treat cancer with new precision using targeted radiation.

Its diagnostic imaging can precisely locate the cancer. Its therapeutics can then deliver isotopes directly to affected cells, thereby protecting healthy tissue.

On 31 May, the company announced additional positive data from its ProstACT SELECT trial of TLX591.

TLX591 is a treatment for adult men with PSMA-positive metastatic castrate-resistant prostate cancer.

Telix said the study reported a median radiographic progression-free survival (rPFS) of 8.8 months.

This builds on prior data from the trial showing a favourable safety profile and biodistribution.

Dr Nat Lenzo, a nuclear oncologist and lead recruiter for the SELECT trial, said:

We are encouraged by this rPFS result …

This is a compelling signal of the potential efficacy of TLX591 in this heavily pre-treated population.

The results further support the development of this candidate in an earlier mCRPC patient population which is the focus of the ProstACT GLOBAL7 Phase III trial and where there remains significant unmet need for effective treatment.

Telix shares also rose by 2.53% on 22 May when the company held its annual general meeting.

In a speech, Telix Chair Kevin McCann said:

Despite all that we have achieved, there is plenty more to come. Indeed, it is the view of Management that 2024 is going to be the biggest year yet for Telix.

By the end of the year, we expect to have launched new products and territories, reported several key development milestones for our therapy programs and progressed some of our very exciting "next generation" assets – such as TLX592 and TLX300.

Motley Fool contributor Bronwyn Allen has positions in Alumina. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PEXA Group, Pinnacle Investment Management Group, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has recommended A2 Milk and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Bapcor, Chalice Mining, Integral Diagnostics, and Winsome Resources shares are dropping

These shares are having a tough session on Monday. But why?

Read more »

Three kids with attitude

3 lower-risk ASX shares I think are perfect for beginners

Here are three ASX shares that are ideal for risk averse investors, in my opinion.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Capitol Health, Capricorn Metals, Credit Clear, and Telix shares are storming higher

These shares are starting the week with a bang. But why?

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares

Why I'm planning to buy Guzman y Gomez shares and own for the long-term

I think this business has a strong outlook.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Materials Shares

Why is this ASX lithium stock crashing 16% today?

Why is this stock having such a poor start to the week?

Read more »

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Share Market News

Guess which ASX All Ords share is raising $1.1 billion to back generative AI

The ASX All Ords company announced a billion dollar capital raising. Here’s why.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »